148 related articles for article (PubMed ID: 2128442)
1. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
2. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
[TBL] [Abstract][Full Text] [Related]
3. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
4. Penetration of ciprofloxacin and fleroxacin into biliary tract.
Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of fleroxacin in man.
Sörgel F; Seelmann R; Naber K; Metz R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
[TBL] [Abstract][Full Text] [Related]
7. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
[TBL] [Abstract][Full Text] [Related]
8. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
[TBL] [Abstract][Full Text] [Related]
9. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
10. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
[TBL] [Abstract][Full Text] [Related]
13. Influence of rifampin on fleroxacin pharmacokinetics.
Schrenzel J; Dayer P; Leemann T; Weidekamm E; Portmann R; Lew DP
Antimicrob Agents Chemother; 1993 Oct; 37(10):2132-8. PubMed ID: 8257135
[TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Heim-Duthoy K; Peltier G; Awni W
Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
[TBL] [Abstract][Full Text] [Related]
17. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
Wagenlehner FM; Wydra S; Onda H; Kinzig-Schippers M; Sörgel F; Naber KG
Antimicrob Agents Chemother; 2003 Dec; 47(12):3789-94. PubMed ID: 14638484
[TBL] [Abstract][Full Text] [Related]
18. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
[TBL] [Abstract][Full Text] [Related]
20. Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.
Dan M; Weidekamm E; Sagiv R; Portmann R; Zakut H
Antimicrob Agents Chemother; 1993 Feb; 37(2):293-6. PubMed ID: 8452360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]